Meeting
2023 ASCO Annual Meeting
A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.
Authors
Qiuxiang Ou
Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China
Qiuxiang Ou , Miao-fang Wu , Yutong Ma , Xiaoying Wu , Yan Shi , Minyi Zhu , Yang Shao , Jing Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3140)
DOI
10.1200/JCO.2023.41.16_suppl.3140
Abstract #
3140
Poster Bd #
338
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Prevalence of germline mutations and homologous recombination deficiency (HRD) in a real-world biliary tract cancer (BTC) cohort.
First Author: Robin Kate Kelley